{"title":"Management of Ureteral Strictures: NYU Case of the Month, October 2018.","authors":"Lee C Zhao","doi":"10.3909/riu0824B","DOIUrl":"10.3909/riu0824B","url":null,"abstract":"40-year-old man developed a 4-cm proximal ureteral stricture following ureteroscopy and laser lithotripsy for an impacted ureteral stone at an outside institution. The patient underwent ureteral dilation, endoureterotomy, and stent placement. After stent removal, he developed pain and hydronephrosis and underwent nephrostomy placement.","PeriodicalId":21185,"journal":{"name":"Reviews in urology","volume":"20 4","pages":"177-178"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3909/riu0824B","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36975474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Vassilios M Skouteris, E David Crawford, Vladimir Mouraviev, Paul Arangua, Marios Panagiotis Metsinis, Michael Skouteris, George Zacharopoulos, Nelson N Stone
{"title":"Transrectal Ultrasound-guided Versus Transperineal Mapping Prostate Biopsy: Complication Comparison.","authors":"Vassilios M Skouteris, E David Crawford, Vladimir Mouraviev, Paul Arangua, Marios Panagiotis Metsinis, Michael Skouteris, George Zacharopoulos, Nelson N Stone","doi":"10.3909/riu0785","DOIUrl":"https://doi.org/10.3909/riu0785","url":null,"abstract":"<p><p>Herein, the authors compare morbidity in men who underwent both transrectal ultrasound-guided (TRUS) prostate biopsy and transperineal mapping biopsy (TPMB) at two institutions with extensive experience in both procedures. We also identified strategies and predictive factors to reduce morbidity for both procedures. In our study, 379 men from two institutions, of which 265 (69.9%) had a prior TRUS-guided biopsy, also had TPMB performed via a template with biopsies taken at 5-mm intervals. Men in the TRUS group had a median of 12 cores sampled whereas the TPMB group had 51.5 (range, 16-151). The median biopsy density was 1.1 core/cc prostate volume. Median age and prostate-specific antigen (PSA) level were 65 years (range, 34-86) and 5.5 ng/mL (range, 0.02-118). Of these men, 11 of 265 (4.2%) who had TRUS biopsy developed urinary tract infection compared with 3 of 379 (0.79%) of those with mapping biopsy. Infection was 14.8% in TRUS biopsy group with 13 or more cores versus 2.9% in those with 12 or less (OR, 5.8; 95% CI, 1.6-21.2; <i>P</i> = 0.003). No men developed retention after TRUS biopsy whereas 30 of 379 (7.9%) did following TPMB. Older age, larger prostate volume (PV), and higher core number were associated with retention. On linear regression only age (<i>P</i> = 0.010) and PV (<i>P</i> = 0.016) remained as significant associations. Men older than 65 years had 12.8% versus 3.9% (OR, 3.7; 95% CI, 1.6-8.4, <i>P</i> = 0.001) and PV greater than 42 cc had 13.4% versus 2.7% (OR, 5.7; 95% CI, 2.1-15.1) retention incidence. In the present study TPMB is rarely associated with infection (0.78%) but more commonly with urinary retention (7.9%). Men older than 65 years and with PV greater than 42 cc were at four to five times greater retention risk. Consideration should be given to discharging these men with a urinary catheter following TPMB.</p>","PeriodicalId":21185,"journal":{"name":"Reviews in urology","volume":"20 1","pages":"19-25"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3909/riu0785","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36255998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Christopher M Pieczonka, Przemyslaw Twardowski, Joseph Renzulli, Jason Hafron, Deborah M Boldt-Houle, Stuart Atkinson, Scott Eggener
{"title":"Effectiveness of Subcutaneously Administered Leuprolide Acetate to Achieve Low Nadir Testosterone in Prostate Cancer Patients.","authors":"Christopher M Pieczonka, Przemyslaw Twardowski, Joseph Renzulli, Jason Hafron, Deborah M Boldt-Houle, Stuart Atkinson, Scott Eggener","doi":"10.3909/riu0798","DOIUrl":"10.3909/riu0798","url":null,"abstract":"<p><p>Evidence suggests lower nadir testosterone levels during the first year of androgen deprivation therapy improve advanced prostate cancer clinical outcomes. We evaluated pivotal trials for subcutaneously administered leuprolide acetate (1-, 3-, 4-, and 6-month doses) to determine nadir testosterone levels. Pooled analysis showed 99%, 97%, and 91% of patients reached nadir testosterone ≤20, ≤10, and ≤5 ng/dL respectively (median ≤3 ng/dL). Across all available categories, $88% of patients reached nadir testosterone ≤5 ng/dL, and <3% experienced a microsurge. Achievement and maintenance of low nadir testosterone levels may improve progression-free survival and time to onset of castrate-resistant prostate cancer.</p>","PeriodicalId":21185,"journal":{"name":"Reviews in urology","volume":"20 2","pages":"63-68"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6168320/pdf/RIU020002_063.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36599625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Testicular Torsion.","authors":"Grace S Hyun","doi":"10.3909/riu0800","DOIUrl":"https://doi.org/10.3909/riu0800","url":null,"abstract":"","PeriodicalId":21185,"journal":{"name":"Reviews in urology","volume":"20 2","pages":"104-106"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3909/riu0800","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36559271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Management of Obstructive Benign Prostatic Hyperplasia With a >200 mL Gland.","authors":"Christopher E Kelly","doi":"10.3909/riu0795","DOIUrl":"https://doi.org/10.3909/riu0795","url":null,"abstract":"A 78-year-old man presented with longstanding and progressive lower urinary tract symptoms (LUTS). Predominant symptoms were decreased flow, sensation of incomplete emptying, and nocturia x1-3. The patient’s LUTS progressed despite his being on a high-dose alphablocker and a 5-alpha reductase inhibitor. He had one episode of acute urinary retention and one urinary tract infection in the past 6 months. His American Urological Association Symptom Score (AUASS) was 24.","PeriodicalId":21185,"journal":{"name":"Reviews in urology","volume":"20 1","pages":"43-45"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6003305/pdf/RIU020001_043.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36256003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Management of Penile Cancer.","authors":"Marc A Bjurlin, Danil V Makarov","doi":"10.3909/riu2001NYUCOM","DOIUrl":"https://doi.org/10.3909/riu2001NYUCOM","url":null,"abstract":"","PeriodicalId":21185,"journal":{"name":"Reviews in urology","volume":"20 1","pages":"46-48"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6003306/pdf/RIU020001_046.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36256004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Navin Shah, Vladimir Ioffe, Thomas Huebner, Ivelina Hristova
{"title":"Prostate Biopsy Characteristics: A Comparison Between the Pre- and Post-2012 United States Preventive Services Task Force (USPSTF) Prostate Cancer Screening Guidelines.","authors":"Navin Shah, Vladimir Ioffe, Thomas Huebner, Ivelina Hristova","doi":"10.3909/riu0793","DOIUrl":"https://doi.org/10.3909/riu0793","url":null,"abstract":"<p><p>To compare prostate cancer (PCa) characteristics diagnosed by prostate biopsy (Pbx) in the 3 years before and after the 2012 United States Preventive Services Task Force (USPSTF) recommendations for PCa screening, we completed a retrospective comparative analysis of 402 sequential PCa patients diagnosed from 2010 to 2012 (3 years) with 552 PCa patients diagnosed from 2015 to 2017 (3 years). Data was collected on patient age, race, total number of biopsies performed, prostate specific antigen (PSA), Gleason sum score (GSS), and digital rectal examination (DRE). The data was analyzed to determine whether the 2012 USPSTF screening recommendations affected PCa characteristics. Two study groups were defined, Group A and Group B, prior to and after the 2012 USPSTF screening recommendations, respectively. In Group A (pre- 2012 USPSTF recommendations), 567 patients/year underwent a Pbx versus Group B, 398 patients/year, a 30% reduction post-USPSTF. The annual positive Pbx rate for Group A is 134/year versus Group B 184/year, a 37.3% increase post-USPSTF. Group A had high-grade PCa (GSS 7-10) in 51.5% versus Group B in 60.1%, an 8.6% increase post-USPSTF. In Group B, the total number of positive biopsies was increased by 100%. This study shows that in Group B, the Pbx rate decreased by 30% but the annual PCa detection rate increased by 37%. High-grade GSS (7-10) PCa increased by 8.6%. Despite a reduction in the total number of prostate biopsies by 30%, there was a 100% increase in the total number of positive prostate biopsies.</p>","PeriodicalId":21185,"journal":{"name":"Reviews in urology","volume":"20 2","pages":"77-83"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6168329/pdf/RIU020002_077.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36599627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Management of Testicular Cancer: NYU Case of the Month, November 2018.","authors":"James Wysock","doi":"10.3909/riu0824C","DOIUrl":"https://doi.org/10.3909/riu0824C","url":null,"abstract":"","PeriodicalId":21185,"journal":{"name":"Reviews in urology","volume":"20 4","pages":"179-181"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6375001/pdf/RiU020004_0179.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36975475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Azoospermia With Testosterone Therapy Despite Concomitant Intramuscular Human Chorionic Gonadotropin: NYU Case of the Month, July 2018.","authors":"Bobby Najari","doi":"10.3909/riu0814","DOIUrl":"https://doi.org/10.3909/riu0814","url":null,"abstract":"Past Medical History The patient’s past medical history was notable for a diagnosis of hypogonadism a year earlier. The patient had complained of fatigue and difficulty recovering from sports injuries. A morning total testosterone level was 250 ng/dL (normal, 30-1100 ng/dL). The patient was started on intramuscular testosterone cypionate, 100 mg weekly. In addition, he was prescribed oral anastrozole, 1 mg, and intramuscular human chorionic gonadotropin (HCG), 500 IU, both twice weekly. The patient had been assured that this regimen would allow for fertility while he was taking exogenous testosterone. The rest of the patient’s medical and surgical history was significant for anxiety and left knee surgery for a torn meniscus. His medications included trazadone and clonazepam. He denied smoking or using illicit drugs and had no relevant family history. He was an investment banker and denied genital trauma or exposure to toxic or radioactive agents.","PeriodicalId":21185,"journal":{"name":"Reviews in urology","volume":"20 3","pages":"137-139"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6241897/pdf/RiU020003_137.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36715212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Carl A Olsson, Hugh J Lavery, Kamlesh K Yadav, Ann E Anderson, Deepak Kapoor
{"title":"Histologic Changes in Prostate Cancer Detected Subsequent to the 2012 United States Preventive Services Task Force (USPSTF) Prostate Cancer Screening Recommendation.","authors":"Carl A Olsson, Hugh J Lavery, Kamlesh K Yadav, Ann E Anderson, Deepak Kapoor","doi":"10.3909/riu0815","DOIUrl":"https://doi.org/10.3909/riu0815","url":null,"abstract":"<p><p>We report changes in the histopathology of prostate cancer diagnosed in a large urology group practice after the final United States Preventive Services Task Force (USPSTF) Grade D recommendation against prostate-specific antigen screening. All prostate biopsies performed from 2011 through 2015 in a large urology group practice were retrospectively reviewed; 2012 was excluded as a transition year. The changes in biopsy data in years following the USPSTF decision (2013-2015) were then compared with baseline (2011). A total of 10,944 biopsies were evaluated during the study period. Positive biopsy rates rose from 39.1% at baseline to 45.2% in 2015 (<i>P</i> < 0.01) with a marked shift toward more aggressive cancer throughout the study period. The absolute number of patients presenting with Gleason Grade Group 4 or 5 increased from 155/year at baseline to 231, 297, and 285 in 2013, 2014, and 2015, respectively (<i>P</i> < 0.05), unrelated to age or racial changes over time. Black men represented 16% of the cohort. Since the USPSTF recommendation against prostate cancer screening, trends toward a substantial upward grade migration and increased volume of cancers were noted in a cohort of nearly 11,000 patients in a real-world clinical practice. Additionally, continuing reductions in cancer detection in the United States may exacerbate these trends.</p>","PeriodicalId":21185,"journal":{"name":"Reviews in urology","volume":"20 3","pages":"125-130"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6241894/pdf/RiU020003_125.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36763015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}